CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

BACKGROUND: Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Brooks, Jennifer D., Comen, Elizabeth A., Reiner, Anne S., Orlow, Irene, Leong, Siok F., Liang, Xiaolin, Mellemkjær, Lene, Knight, Julia A., Lynch, Charles F., John, Esther M., Bernstein, Leslie, Woods, Meghan, Doody, David R., Malone, Kathleen E., Bernstein, Jonine L.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288916/
https://ncbi.nlm.nih.gov/pubmed/30526633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-1083-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars